Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMBeacon Phase 2 study of ALN-6400 in females with von Willebrand disease and heavy menstrual bleeding
2025-524967-19-00Phase 2Authorised
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Sep 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in von Willebrand disease (VWD) comparing ALN-6400 with Placebo (2 arms). Primary endpoint: Frequency of adverse events. Planned start Sep 2026; status: authorised.
02
Drugs
ALN-6400
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2025-524967-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524967-19-00.